BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kimura M, Usami E, Kanematsu T, Iwai M, Yoshimura T, Mori H, Sugiyama T, Teramachi H. Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer. Mol Clin Oncol 2014;2:466-72. [PMID: 24772319 DOI: 10.3892/mco.2014.260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Zheng Y, Zhu XQ, Ren XG. Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6884. [PMID: 28614219 DOI: 10.1097/MD.0000000000006884] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
2 Liu Y, Wang Q, Lu Y, Deng H, Zhou X. Synergistic enhancement of cytotoxicity against cancer cells by incorporation of rectorite into the paclitaxel immobilized cellulose acetate nanofibers. International Journal of Biological Macromolecules 2020;152:672-80. [DOI: 10.1016/j.ijbiomac.2020.02.184] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]